Conferences Details: | |
Event: | Chardan Virtual 4TH Annual |
Format: | Fireside Chat |
Date: | |
Time: | |
Location: | Webcast Link - or at the company’s website (click here) |
About
NeuBase is accelerating the genetic revolution using a new class of synthetic medicines. NeuBase’s designer PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com.
NeuBase Investor Contact:
Managing Director
Daniel@lifesciadvisors.com
OP: (617) 430-7576
NeuBase Media Contact:
LifeSci Public Relations
cait@lifescipublicrelations.com
OP: (646) 751-4366
Source:
2020 GlobeNewswire, Inc., source